Genscript Biotech Management
Management Kriterienprüfungen 3/4
Genscript Biotech CEO ist Sherry Shao , ernannt in Jul 2021, hat eine Amtszeit von 5.08 Jahren. Die jährliche Gesamtvergütung beträgt $2.81M , bestehend aus 14.4% Gehalt und 85.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.073% der Aktien des Unternehmens, im Wert von HK$28.66M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.4 Jahre bzw. 3.4 Jahre.
Wichtige Informationen
Sherry Shao
Geschäftsführender
US$2.8m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 14.43% |
| Amtszeit als Geschäftsführer | 5.1yrs |
| Eigentum des Geschäftsführers | 0.07% |
| Durchschnittliche Amtszeit des Managements | 4.4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 3.4yrs |
Jüngste Management Updates
Recent updates
1548: New Expression Platform Will Support Future Cell Therapy Upside
Analysts have made a small adjustment to their price target for Genscript Biotech to HK$17.68. This reflects updated views on the company’s fair value, discount rate, revenue growth, profit margin and future P/E assumptions.1548: European mRNA Buildout And Cell Therapy Data Will Support Future Upside
Analysts have made a very small upward adjustment to Genscript Biotech's fair value estimate, moving the target from about HK$17.67 to roughly HK$17.67. They refreshed assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect current views on the business.1548: European mRNA Expansion Will Support Future Upside Potential
Analysts have kept their HK$17.67 price target for Genscript Biotech broadly unchanged, with only slight tweaks to the discount rate and future P/E assumptions shaping this latest narrative update. What's in the News GenScript plans to put amendments to its fourth amended and restated memorandum and articles of association to a shareholder vote at the AGM on June 5, 2026, and proposes adopting a fifth amended and restated version of these governing documents (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have trimmed their price target for Genscript Biotech to about HK$17.67 from roughly HK$18.56, citing slightly lower fair value estimates and a modestly reduced future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its mRNA platform and reinforcing Europe as a core part of its integrated R&D and production network (Key Developments).1548: European mRNA Expansion And AI Integration Will Support Future Upside Potential
Analysts have slightly adjusted their view on Genscript Biotech, trimming the implied fair value from about HK$18.95 to around HK$18.56 as they fine tune assumptions on revenue growth, profit margin and future P/E levels. What's in the News Genscript opened its first European mRNA production site in Delft, the Netherlands, adding gene design, synthesis, vector engineering, IVT mRNA production, GenCap mRNA capping, UTR optimization and formulation support within a single facility (Key Developments).
Heavy Automation Costs And Legend Exposure Will Slowly Give Way To Healthier Margins
Catalysts About Genscript Biotech Genscript Biotech is a global biotech group focused on gene to protein research tools, biologics CRDMO services and industrial enzyme products. What are the underlying business or industry changes driving this perspective?1548: European mRNA Expansion Will Support Ongoing Upside Potential
Analysts have trimmed their HK$ price target on Genscript Biotech from about HK$22.12 to around HK$18.95, citing updated assumptions for slower revenue growth, a higher profit margin profile, and a lower future P/E multiple in their models. What's in the News GenScript opened its first European mRNA production site in Delft, the Netherlands, expanding its global mRNA platform with end to end capabilities that include gene design, vector engineering, IVT mRNA production, GenCap mRNA capping technology, UTR optimization, and formulation support (Key Developments).1548: Higher Future P/E Assumptions Will Support Ongoing Upside Potential
Analysts have adjusted their HK$ price target for Genscript Biotech to reflect updated views on discount rate, long term profit margins and a higher assumed future P/E multiple. This has resulted in a modest recalibration of fair value rather than a wholesale shift in the investment case.1548: Slightly Lower Future P/E Will Still Support Attractive Upside Potential
Analysts have trimmed their price target on Genscript Biotech to reflect a slightly lower assumed future P/E multiple, while keeping fair value broadly unchanged at about HK$22.12. They cite fine tuning of discount rate and margin assumptions rather than any major shift in the core outlook.1548: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have trimmed their fair value estimate for Genscript Biotech from $23.52 to $22.12, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Genscript Biotech held an Analyst/Investor Day, giving the market a closer look at its business, capital plans, and the assumptions that feed into analyst models (Key Developments).Unpleasant Surprises Could Be In Store For Genscript Biotech Corporation's (HKG:1548) Shares
With a median price-to-sales (or "P/S") ratio of close to 5.5x in the Life Sciences industry in Hong Kong, you could be...Is Genscript Biotech Corporation (HKG:1548) Trading At A 44% Discount?
Key Insights Genscript Biotech's estimated fair value is HK$30.13 based on 2 Stage Free Cash Flow to Equity Genscript...We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings
The market for Genscript Biotech Corporation's ( HKG:1548 ) shares didn't move much after it posted weak earnings...Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Despite a sharp decline in consensus revenue growth forecasts and a substantial jump in future P/E, analysts have raised Genscript Biotech's fair value estimate from HK$21.61 to HK$23.01. What's in the News GenScript Biotech launched a new global brand platform, "Scripting Possibilities," alongside a refreshed visual identity and expanded marketing initiatives to drive growth and strengthen global brand presence.Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2025 | US$3m | US$405k | -US$533m |
| Sep 30 2025 | n/a | n/a | -US$264m |
| Jun 30 2025 | n/a | n/a | US$5m |
| Mar 31 2025 | n/a | n/a | -US$31m |
| Dec 31 2024 | US$4m | US$352k | -US$67m |
| Jun 30 2024 | n/a | n/a | US$419m |
| Mar 31 2024 | n/a | n/a | US$421m |
| Dec 31 2023 | US$2m | US$353k | US$423m |
Vergütung im Vergleich zum Markt: SherryDie Gesamtvergütung ($USD2.81M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD1.02M).
Entschädigung vs. Einkommen: SherryDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Sherry Shao (46 yo)
Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 6.5m | |
| CEO & COO | 5.1yrs | US$2.81m | 0.073% HK$ 28.7m | |
| Co-Founder | 24.6yrs | US$803.00k | 0.040% HK$ 15.7m | |
| Co-Founder & Executive Director | 3.7yrs | US$645.00k | keine Daten | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.049% HK$ 19.4m | |
| Chief Financial Officer | 1.3yrs | keine Daten | keine Daten | |
| General Counsel & Chief Compliance Officer | no data | keine Daten | keine Daten | |
| Head of Corporate Communications | no data | keine Daten | keine Daten | |
| Chief Marketing Officer for GenScript Life Science Group | 1.8yrs | keine Daten | keine Daten | |
| Head of Global Diversity | no data | keine Daten | keine Daten | |
| Head of Sustainability | no data | keine Daten | keine Daten | |
| President of GenScript Life Science Group | no data | keine Daten | keine Daten |
Erfahrenes Management: 1548Das Führungsteam des Unternehmens gilt als erfahren (4.4 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 11yrs | US$525.00k | 0.016% HK$ 6.5m | |
| Co-Founder | 11.3yrs | US$803.00k | 0.040% HK$ 15.7m | |
| Co-Founder & Executive Director | 4.3yrs | US$645.00k | keine Daten | |
| Chief Strategy Officer & Executive Director | 5.8yrs | US$595.00k | 0.049% HK$ 19.4m | |
| Independent Non-executive Director | 1.9yrs | US$70.00k | 0.00030% HK$ 118.6k | |
| Member of Advisory Board | 2.6yrs | keine Daten | keine Daten | |
| Member of Advisory Board | 6.9yrs | keine Daten | keine Daten | |
| Independent Non-Executive Director | 1.9yrs | US$100.00k | keine Daten | |
| Member of Scientific Advisory Board | 2.4yrs | keine Daten | keine Daten | |
| Independent Non-Executive Director | 7.8yrs | US$100.00k | 0.00068% HK$ 268.8k | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | keine Daten | |
| Independent Non-Executive Director | 2.3yrs | US$100.00k | keine Daten |
Erfahrener Vorstand: 1548Die Vorstandsmitglieder gelten als erfahren (3.4 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/02 02:07 |
| Aktienkurs zum Tagesende | 2026/07/31 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Genscript Biotech Corporation wird von 12 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Wai Chak Yuen | Daiwa Securities Co. Ltd. |